Af­ter No­var­tis’ Adakveo was pulled in Eu­rope, the UK fol­lows suit 

No­var­tis is pulling Adakveo from the UK mar­ket as its clin­i­cal ben­e­fits no longer out­weigh its risks, a month af­ter the Med­i­cines and Health­care prod­ucts Reg­u­la­to­ry Agency (MHRA) re­voked the mar­ket­ing au­tho­riza­tion of the drug.

The MHRA re­voked the mar­ket­ing au­tho­riza­tion of Adakveo on Jan. 10. The Eu­ro­pean Com­mis­sion al­so pulled the drug last Au­gust, fol­low­ing an EMA rec­om­men­da­tion in May.

The re­voked au­tho­riza­tions fol­low the com­ple­tion of No­var­tis’ Phase III STAND tri­al, which failed to show Adakveo per­formed bet­ter than place­bo. The drug is still ap­proved in the US mar­ket and No­var­tis “con­tin­ues to dis­cuss the STAND study re­sults with FDA,” ac­cord­ing to the com­pa­ny’s an­nu­al re­port on Jan 31.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER